
Revolution Medicines Announces Pricing of $750.0 Million Raised Public Offering of Common Stock and Pre-Funded Warrants from Investing.com
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-dependent cancers, today announced pricing for 14,130,436 shares of its common stock at a public offering price of $46.00 per share, previously taking discounts and commissions, and, instead of ordinary shares,…